The Q4 result was announced after market hours on Saturday, 11 May 2013.
Meanwhile, the S&P BSE Sensex was down 144.41 points or 0.72% at 19,977.91.
On BSE, 26,000 shares were traded in the counter as against average daily volume of 10,539 shares in the past one quarter.
The stock hit a high of Rs 192 and a low of Rs 185 so far during the day. The stock had hit a 52-week high of Rs 216.80 on 10 January 2013. The stock had hit a 52-week low of Rs 124.25 on 4 June 2012.
The stock had outperformed the market over the past one month till 11 May 2013, surging 9.43% compared with the Sensex's 8.52% rally. The scrip had, however, underperformed the market in past one quarter, rising 0.66% as against Sensex's 3.4% gain.
The small-cap pharmaceutical company has equity capital of Rs 18.09 crore. Face value per share is Rs 2.
Unichem Laboratories' net profit surged 57.2% to Rs 129.60 crore on 25.6% growth in net sales to Rs 996.86 crore in the year ended 31 March 2013 (FY 2013) over the year ended 31 March 2012 (FY 2012).
On consolidated basis, Unichem Laboratories' net profit surged 58.9% to Rs 113.23 crore on 23.8% growth in net sales to Rs 1072.45 crore in FY 2013 over FY 2012.
Unichem Laboratories' board of directors at a meeting held on Saturday, 11 May 2013, recommended dividend of Rs 4.50 per share for FY 2013.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche areas of cardiology, neurology and other orthopadics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms.
Powered by Capital Market - Live News
